Answers are grounded in this paper and cite their sources.
Background By 31 December 2022, the United States Food and Drug Administration (FDA) has approved 12 biosimilar monoclonal antibody cancer treatments. This study detected disproportionate adverse event (AE) reporting signals and compared safety profile of individual biosimilars to their originator biologics and between each pair of biosimilars.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: